Skip to main content

Table 3 Cox proportional hazard analysis for progression-free survival

From: Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis

 

Univariate

Multivariate

Set 1

Set 2

 h (95%CI)

p-value

HR (95%CI)

P-value

HR (95%CI)

p-value

Age, ≥ 65

1.13 (0.68–1.87)

0.645

    

Sex, men

1.00 (0.31–3.19)

0.996

    

Smoking status, ever-smokers

0.35 (0.13–1.00)

0.049

0.51 (0.17–1.54)

0.232

0.35 (0.12–1.08)

0.068

ECOG-PS, 0–1

0.37 (0.19–0.71)

0.003

0.42 (0.21–0.84)

0.015

0.45 (0.23–0.89)

0.022

Stage, III

0.96 (0.57–1.62)

0.889

    

Pathology, uNSCLC (vs. cNSCLC)

0.93 (0.57–1.50)

0.757

1.00 (0.61–1.63)

0.996

1.01 (0.62–1.65)

0.970

PD-L1,

      

≥ 50%

0.43 (0.25–0.75)

0.003

0.44 (0.26–0.77)

0.004

  

≥ 1%

0.58 (0.36–0.95)

0.029

  

0.56 (0.33–0.94)

0.029

Line of treatment, 1st-line

0.81 (0.39–1.71)

0.584

    
  1. CI, confidence interval; cNSCLC, common non-small cell lung cancer; ECOG-PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; PD-L1, programmed death ligand-1; uNSCLC, uncommon non-small cell lung cancer